

Ref: FOI/GS/ID 7118

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

31 December 2021

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Ovarian cancer.

*You asked:*

- 1. How many patients have been treated for advanced (FIGO Stages III and IV) high-grade ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer ovarian cancer patients to another trust, if so which one?*
- 2. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:*
  - a. Paclitaxel in combination with a platinum-based compound*
  - b. Platinum-based therapy alone (cisplatin or carboplatin)*
  - c. Bevacizumab in combination with paclitaxel and carboplatin*
  - d. Olaparib*
  - e. Olaparib + Bevacizumab*
  - f. Niraparib*
  - g. Rucaparib*
- 3. Of the ovarian cancer patients (any stage) treated over the last 3 months, how many patients:*
  - a. Received HRD (homologous recombination deficiency) testing*
  - b. Received BRCA testing*
  - c. Tested HRD positive*
  - d. Tested BRCA positive (BRCAm)*
- 4. If data for HRD testing is available, please provide how many HRD positive patients were treated in the last 3 months with:*
  - a. Olaparib*
  - b. Olaparib + Bevacizumab*
  - c. Niraparib*
  - d. Other treatments*

5. If data for HRD and BRCA testing is available, please provide how many HRD positive-BRCA positive patients were treated in the last 3 months with:

- a. Olaparib
- b. Olaparib + Bevacizumab
- c. Niraparib
- d. Other treatments

Trust response:

1. This is the information recorded for patients who have started their first definitive treatment between July 2021 and October 2021 for the selected diagnoses

**First Definitive Treatment July to October 2021**

<b>Diagnosis</b>	<b>Stage III</b>	<b>Stage IV</b>	<b>Grand Total</b>
Primary Peritoneal	2		2
Ovarian	6	3	9
Fallopian		1	1
<b>Grand Total</b>	<b>8</b>	<b>4</b>	<b>12</b>

2.

- a. 18
  - b. 17
  - c. 2
  - d. 8
  - e. 0
  - f. 12
  - g. 4
- 3, 4 and 5.

The Trust has estimated that it will cost more than the appropriate limit to consider this part of your request as a detailed clinical audit would be required in order to provide this information. The appropriate limit is specified in regulations and represents the estimated cost of one person spending 3½ working days in determining whether the Trust holds the information, locating, retrieving and extracting the information. Under Section 12 of the Freedom of Information Act 2000 the Trust is not obliged to comply with this part of your request and we will not be processing this part of your request further.